DE60228864D1 - Wässrige proteinformulierung mit verzögerter freigabe - Google Patents

Wässrige proteinformulierung mit verzögerter freigabe

Info

Publication number
DE60228864D1
DE60228864D1 DE60228864T DE60228864T DE60228864D1 DE 60228864 D1 DE60228864 D1 DE 60228864D1 DE 60228864 T DE60228864 T DE 60228864T DE 60228864 T DE60228864 T DE 60228864T DE 60228864 D1 DE60228864 D1 DE 60228864D1
Authority
DE
Germany
Prior art keywords
delayed release
protein formulation
aqueous protein
aqueous
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60228864T
Other languages
English (en)
Inventor
Basant Sharma
Renzhe Jin
Sunitha Rudolph
Wing K Cheung
Selima Begum
Marian Kelley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Janssen Pharmaceuticals Inc filed Critical Ortho McNeil Janssen Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60228864D1 publication Critical patent/DE60228864D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE60228864T 2001-11-07 2002-10-25 Wässrige proteinformulierung mit verzögerter freigabe Expired - Lifetime DE60228864D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/037,369 US6818613B2 (en) 2001-11-07 2001-11-07 Aqueous sustained-release formulations of proteins
PCT/US2002/036300 WO2003053471A1 (en) 2001-11-07 2002-10-25 Aqueous sustained-release formulations of proteins

Publications (1)

Publication Number Publication Date
DE60228864D1 true DE60228864D1 (de) 2008-10-23

Family

ID=21893975

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228864T Expired - Lifetime DE60228864D1 (de) 2001-11-07 2002-10-25 Wässrige proteinformulierung mit verzögerter freigabe

Country Status (20)

Country Link
US (3) US6818613B2 (de)
EP (1) EP1441771B1 (de)
JP (1) JP2005514394A (de)
CN (1) CN1612752A (de)
AR (1) AR037260A1 (de)
AT (1) ATE407701T1 (de)
AU (1) AU2002343666B2 (de)
BR (1) BR0213992A (de)
CA (1) CA2465890A1 (de)
CY (1) CY1110271T1 (de)
DE (1) DE60228864D1 (de)
DK (1) DK1441771T3 (de)
ES (1) ES2312633T3 (de)
HK (1) HK1066468A1 (de)
MX (1) MXPA04004367A (de)
MY (1) MY136952A (de)
PT (1) PT1441771E (de)
SI (1) SI1441771T1 (de)
TW (1) TWI332845B (de)
WO (1) WO2003053471A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1311285T4 (en) * 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US8937045B2 (en) * 2003-02-28 2015-01-20 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1537876A1 (de) * 2003-12-01 2005-06-08 BioGeneriX AG Formulierung einer Erythropoietin Lösung
US20050209148A1 (en) * 2004-02-20 2005-09-22 Arnon Rosenthal Methods of treating obesity or diabetes using NT-4/5
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
MX2007004676A (es) 2004-10-27 2007-11-14 Univ Denver Analogos de la hormona adrenocorticotropica y metodos relacionados.
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
CA2637826A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
WO2007088479A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
KR20100014674A (ko) 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
CN101679511A (zh) 2007-06-06 2010-03-24 杜门蒂斯有限公司 多肽、抗体可变域和拮抗剂
AU2008261212A1 (en) * 2007-06-15 2008-12-18 University Of Zurich Treatment for Alzheimer' s disease
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
RU2465003C2 (ru) * 2007-12-28 2012-10-27 Херойс Кульцер Гмбх Местное нанесение и препараты эритропоэтина для заживления кожных ран
US8357179B2 (en) * 2009-07-08 2013-01-22 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8529596B2 (en) 2009-07-08 2013-09-10 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US20110009941A1 (en) * 2009-07-08 2011-01-13 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8795345B2 (en) * 2009-07-08 2014-08-05 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8357178B2 (en) * 2009-07-08 2013-01-22 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8795317B2 (en) * 2009-07-08 2014-08-05 Concentric Medical, Inc. Embolic obstruction retrieval devices and methods
PT2637690T (pt) 2010-11-11 2016-12-27 Abbvie Biotechnology Ltd Formulações líquidas de anticorpo anti-tnf-alfa de concentração elevada
JP6016813B2 (ja) 2011-02-04 2016-10-26 コンセントリック メディカル，インク． 塞栓回収デバイス
CN103930124B (zh) 2011-07-01 2021-05-11 生物基因Ma公司 无精氨酸的tnfr：fc-融合多肽组合物及使用方法
TW201842929A (zh) * 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
DE2967337D1 (en) * 1978-06-16 1985-02-07 Kyowa Hakko Kogyo Kk Antithrombotic pharmaceutical preparation containing 2,2'-dithiobis benzamide derivatives and new 2,2'-dithiobis benzamide derivatives
WO1983001198A1 (en) 1981-10-08 1983-04-14 Kurt Frimann Berg Method and composition for treating a patient suffering from interferon-susceptible disorder
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
ES520813A0 (es) * 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
JPS604186A (ja) * 1983-06-21 1985-01-10 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン化合物
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4717717A (en) 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
JP2001515457A (ja) * 1995-06-07 2001-09-18 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 凝集安定化生理活性物質放出用装置
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
KR20040010739A (ko) 1996-02-09 2004-01-31 암젠 인코포레이티드 인터루킨-1 수용체 길항물질을 포함하는 융합 단백질 및 이를 포함하는 제약학적 조성물
AU3908597A (en) 1996-08-02 1998-02-25 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
ES2273434T3 (es) 1997-07-23 2007-05-01 Roche Diagnostics Gmbh Obtencion de la eritropoyetina mediante activacion genica endogena.
ES2208798T3 (es) 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
AU775422B2 (en) 1998-06-15 2004-07-29 Gtc Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion
AU758178B2 (en) 1998-09-04 2003-03-20 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CO5160256A1 (es) 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
JP2002541208A (ja) 1999-04-09 2002-12-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド エリトロポイエチンの薬剤組成物
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins

Also Published As

Publication number Publication date
CA2465890A1 (en) 2003-07-03
EP1441771A1 (de) 2004-08-04
HK1066468A1 (en) 2005-03-24
BR0213992A (pt) 2004-08-31
TW200303215A (en) 2003-09-01
ATE407701T1 (de) 2008-09-15
US7282480B2 (en) 2007-10-16
US20030181361A1 (en) 2003-09-25
CY1110271T1 (el) 2015-01-14
ES2312633T3 (es) 2009-03-01
US6818613B2 (en) 2004-11-16
WO2003053471A1 (en) 2003-07-03
US20050164927A1 (en) 2005-07-28
DK1441771T3 (da) 2009-01-05
PT1441771E (pt) 2008-10-29
EP1441771B1 (de) 2008-09-10
TWI332845B (en) 2010-11-11
CN1612752A (zh) 2005-05-04
JP2005514394A (ja) 2005-05-19
US20030148938A1 (en) 2003-08-07
AU2002343666B2 (en) 2007-04-05
AR037260A1 (es) 2004-11-03
SI1441771T1 (sl) 2009-02-28
MXPA04004367A (es) 2005-05-16
AU2002343666A1 (en) 2003-07-09
MY136952A (en) 2008-12-31

Similar Documents

Publication Publication Date Title
DE60228864D1 (de) Wässrige proteinformulierung mit verzögerter freigabe
ATE506064T1 (de) Analgetika mit verzögerter wirkstoffabgabe
ATE495731T1 (de) Amphetaminsalz-formulierung mit verzögerter wirkstofffreigabe
DE60219383D1 (de) Wässrige Beschichtungszusammensetzung
NO20033143L (no) Farmasoytisk preparat
DE60325511D1 (de) Depot-formulierungen mit verzögerter freisetzung
CY2014009I1 (el) Παρασιτοκτονα σκευασματα
DE60037459D1 (de) Mit tragrumpf versehenes flugzeug
DE50202890D1 (de) Anhängekupplung
DE60213194D1 (de) Haltenadel mit flügel
DE60217545D1 (de) Spritzvorrichtung mit seitlicher betätigung
ATE267592T1 (de) Klare wässrige anästhesierende zusammensetzung
DE60211606D1 (de) Reissverschluss mit Endanschlag
DE60238111D1 (de) Viszeralfettmesser mit tonometer
DE60229399D1 (de) Hgf-hydrogel-zubereitungen mit verzögerter freisetzung
DE60103683D1 (de) Wässrige Pestizidzusammensetzung
NO20025805L (no) Farmasöytisk preparat
ATE450652T1 (de) Wässrige zusammensetzung
DK1361791T3 (da) Agrokemisk formulering
NO20033829D0 (no) Antiviralt preparat
FR2821754B1 (fr) Descenceur autobloquant
NO20026215L (no) Nytt hormonpreparat
ATA2892002A (de) Beschlag
DE60223695D1 (de) Aminosäure-modulierte dosierform mit verlängerter freisetzung
NO20011947L (no) Fiskeredskap

Legal Events

Date Code Title Description
8364 No opposition during term of opposition